moderate - Hospital capital equipment budgets exhibit some cyclicality but are less discretionary than elective procedures. MRI suite construction and equipment upgrades correlate with healthcare system profitability and patient volumes. Economic downturns may delay hospital capital projects 6-12 months, but demographic aging and chronic disease prevalence provide secular tailwinds. Disposables revenue (10-15% of sales) is non-cyclical, tied to MRI scan volumes.

Rising rates create modest headwinds through two channels: (1) Hospital systems face higher borrowing costs for capital projects, potentially delaying MRI suite builds or equipment purchases; (2) IRMD's premium valuation (44x EV/EBITDA) compresses as risk-free rates rise and growth stocks de-rate. However, zero debt insulates the company from financing cost pressures. Rate cuts would support hospital capital spending and multiple expansion.

growth - Investors pay 15x sales and 44x EBITDA for 14% revenue growth, betting on installed base expansion, international penetration, and operating leverage driving 20%+ earnings growth. Small-cap growth funds and healthcare specialists attracted to niche market dominance, asset-light model, and 24% ROE. Momentum investors drove 78% one-year return on earnings beats and margin expansion.